This week in therapeutics




Licensing status

Publication and contact information

Cardiovascular disease

Ischemia/reperfusion injury

(miR-27a); VE-cadherin (CD144; cadherin-5)

Mouse studies suggesting blocking the interaction between miR-27a and VE-cadherin transcripts could help treat ischemia. In a mouse model of hind limb ischemia, an RNA antagomir that inhibits the miR-27a-VE-cadherin interaction decreased edema and increased both blood flow and angiogenesis in ischemic muscle compared with a control antagomir. Next steps include evaluating the blockade of the
miR-27a-VE-cadherin interaction in other arterial injury models and determining the therapeutic window for use of the antagomir.
Mirrx Therapeutics A/S has an IP stake in the blockmir antagomirtechnology used in this work and is developing blockmirs for therapeutic and research use.

SciBX 6(40); doi:10.1038/scibx.2013.1125
Published online Oct. 17, 2013

Patent pending covering use in indications related to vascular edema; available for licensing from Bio-Link Australia Pty. Ltd.

Young, J.A. et al. Blood; published online Sept. 5, 2013;
Contact: Jennifer R. Gamble, The University of Sydney, Sydney,
New South Wales, Australia